Sunflower® announced today that it has engaged MATSUBO Corporation as its exclusive distributor for the Daisy Petal® Perfusion Bioreactor System in Japan. This marks Sunflower’s second commercial partnership within the Asian region, representing a key step in its international growth strategy.
Press Releases
Sunflower® Therapeutics Completes Major Installation of Daisy Petal® Systems at the Serum Institute of India, the World’s Largest Vaccine Manufacturer
Daisy Petal® systems installed in GMP space to enable perfusion fermentation at SIIPL, enabling faster, higher-yield protein production in a compact, user-friendly platform.
Sunflower® Therapeutics Receives First Milestone Payment Through Collaboration with SK bioscience on Cost-Effective HPV Vaccine
Collaboration advances the commercialization of a 10-valent HPV vaccine.
Sunflower® Therapeutics Receives NIH SBIR Funding to Develop an Automated, Continuous Cell Disruption Platform for VLP-Based Vaccine Manufacturing
Platform to advance the large-scale production and purification of virus-like particles (VLPs) for use in cost-effective human vaccines.
Sunflower® Therapeutics Announces Exclusive Distribution Agreement with Alflow Scandinavia A/S
Sunflower® Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, announced today that it has engaged Alflow Scandinavia A/S as its exclusive distributor for the Daisy Petal® Perfusion Bioreactor System in Denmark, Norway, Sweden, and Iceland. This marks Sunflower’s first commercial partnership in Europe, representing a key step in its international growth strategy.
Sunflower® Therapeutics Announces the First System Delivery and Installation of the Daisy Petal® Perfusion Bioreactor System to BioBuilder
The system is installed in the newly commissioned BioBuilder Learning Lab space in Allston Labworks for use in training local students, educators, and incumbent workers to be a passionate part of the growing biotechnology workforce.
Sunflower® Therapeutics Announces an Exclusive Sales Representation Agreement with Optimal Biotech Group
Customers in California, Oregon, Washington, Idaho, Montana, and British Columbia can now purchase the Daisy Petal®
Sunflower® Therapeutics Engages PharmNXT Biotech LLP as Distributor for the Daisy Petal® Perfusion Bioreactor System
Daisy Petal® is now commercially launched and available for sale in India, Singapore, Thailand, Indonesia, Malaysia, and South Korea
Sunflower® Therapeutics Closes $3M Simple Agreement for Future Equity (SAFE) with Oversubscription
Sunflower® Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, announced today the oversubscription of a $3M Simple Agreement for Future Equity (SAFE), which underscores ongoing support for the company’s commercial goals.
Sunflower® Therapeutics’ Daisy Petal® Named “Lifescience Manufacturing Solution of the Year” by BioTech Breakthrough
Recognizing Innovation in Global Life Sciences and Biotechnology HINGHAM, MA, NOVEMBER 19, 2024 ‒ At Sunflower Therapeutics, we’re on a mission to make protein production more accessible, efficient, and cost-effective, and it’s exciting to see our efforts recognized!...
